TickerFacts.

Septerna, Inc. (SEPN): R&D Expense

Annual figures by period end, from SEC filings.

$97.58M
Year ended 2025-12-31
$120.79M
Trailing 12 months to 2026-06-30
2023-12-31: $35.98M2024-12-31: $65.34M2025-12-31: $97.58M$97.58M
2023-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$97.58M+49.4%2026-03-09, From 2025-01-01
2024-12-31$65.34M+81.6%2026-03-09, From 2024-01-01
2023-12-31$35.98Mn/a2025-03-27, From 2023-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Septerna, Inc. (SEPN)2025-12-31$97.58M+49.4%
Protagonist Therapeutics, Inc (PTGX)2025-12-31$159.29M+15.3%
Aquestive Therapeutics, Inc. (AQST)2025-12-31$17.19M-15.2%
Cumberland Pharmaceuticals Inc (CPIX)2025-12-31$5.57M+15.6%
Xilio Therapeutics, Inc. (XLO)2025-12-31$56.04M+36.0%
Gossamer Bio, Inc. (GOSS)2025-12-31$174.09M+25.7%
Wave Life Sciences, Inc. (WVE)2025-12-31$182.78M+14.5%
Lexicon Pharmaceuticals, Inc. (LXRX)2025-12-31$61.12M-27.7%
Biofrontera Inc. (BFRI)2025-12-31$3.72M+78.0%

Compare SEPN, PTGX, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗